Back to discover
Disease

Cushing's Syndrome

Late-stage therapeutic developmentEmerging researchRising momentum
6
Publications
13
Clinical trials
1
Related conditions
2
Related treatments
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Toward Systems-Level Metabolic Analysis in Endocrine Disorders and Cancer.

Research2023-11-21Endocrinology and metabolism (Seoul, Korea)

The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

Research2008-03-11The Journal of clinical endocrinology and metabolism

Diagnosis and complications of Cushing's syndrome: a consensus statement.

Research2003-12-01The Journal of clinical endocrinology and metabolism

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies

Approval — Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults. (2020)

Ketoconazoleapproved

Accelerated approval — Ketoconazole Esteve is indicated for the treatment of endogenous Cushing’s syndrome in ad… (2014)

Research-associated treatments

Clinical trials

10 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
13
All trials
5
Active
3
Late-stage
5
Completed
Recruiting
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2020emaApprovalOsilodrostat phosphate· Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults. source ↗
2014emaAccelerated approvalKetoconazole· Ketoconazole Esteve is indicated for the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

6 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20032024
Most influential
Recent publications
Major themes8
  • Cushing Syndrome4
  • Adenoma1
  • Adrenocortical Adenoma1
  • Antioxidants1
  • Cardiovascular Diseases1
  • Diabetes Mellitus1
  • Frailty1
  • Metabolic Syndrome1
Leading journals5
  • The Journal of clinical endocrinology and metabolism2
  • Endocrinology and metabolism (Seoul, Korea)1
  • European journal of endocrinology1
  • Frontiers in endocrinology1
  • Journal of internal medicine1
Leading researchers8
  • Findling JW2
  • Newell-Price J2
  • Nieman LK2
  • Achenbach SJ1
  • Ambroziak U1
  • Angeli A1
  • Arnaldi G1
  • Athimulam S1
Affiliations (unnormalised)6
  • Chungnam National University College of Medicine1
  • Department of Veterinary Clinical Sciences1
  • Division of Clinical Trials and Biostatistics1
  • Erasmus MC University Medical Center Rotterdam1
  • Evangelismos Hospital1
  • General Hospital Koprivnica1

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Cushing syndrome is a condition caused by prolonged exposure to excess cortisol or other glucocorticoids from endogenous or exogenous sources. It is characterized by features such as upper body obesity, osteoporosis, hypertension, diabetes mellitus, hirsutism, amenorrhea, and excess body fluid. Endogenous Cushing syndrome, also called spontaneous hypercortisolism, is divided into ACTH-dependent and ACTH-independent forms.

Causes

The syndrome results from prolonged exposure to excess glucocorticoids, either from outside the body or from endogenous overproduction. The supplied grounding specifically distinguishes endogenous disease into ACTH-dependent causes and ACTH-independent causes. No more specific etiologies are supported in the grounding provided.

Pathophysiology

The core biological mechanism is chronic glucocorticoid excess, which drives the clinical syndrome and its metabolic complications. The literature grounding links Cushing syndrome to metabolic dysregulation, cardiometabolic deterioration, and oxidative stress associated with adrenal hormone imbalance. Endogenous disease is mechanistically grouped into ACTH-dependent and ACTH-independent hypercortisolism.

Risk factors

The grounding supports prolonged exposure to glucocorticoids as the main risk factor for developing Cushing syndrome. It also supports endogenous ACTH-dependent or ACTH-independent hypercortisolism as underlying risk contexts. No additional demographic or clinical risk factors are supported by the supplied material.

Current standard of care

The supplied review and guideline abstracts support diagnostic evaluation and assessment of complications as central management themes. They do not provide treatment modalities beyond diagnosis-focused guidance, so no standard therapeutic class can be stated from the grounding alone. Accordingly, this field is null.

AI-generated summary grounded in MeSH and 5 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.